Drug
Intravitreal Aflibercept
Intravitreal Aflibercept: highest development phase Post-Market, developed by Regeneron. 2 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Regeneron
Trials
| Drug | Phase | Indication |
|---|---|---|
| Intravitreal Aflibercept Injection (IAI) NCT01722045 | Post-Market | Age - Related Macular Degeneration (AMD) |
| Intravitreal Aflibercept NCT04588948 | Phase 2 | Diabetic Macular Edema |
Latest
No recent events.
Follow Intravitreal Aflibercept on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.